Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/991010?src=rss